Home › Bladder Cancer › NCT07048496
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Inclusion criteria for patients in Cohort 1 * Age 18 years or older; * completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders * Age 18 years or older; * experience with the delivery of BCG delivery for more than 2 years Cohort 2 inclusion criteria * Age 18 years or older; * diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy Exclusion Criteria: Cohort 1 exclusion criteria • inability to provide informed consent Cohort 2 exclusion criteria * inability to provide informed consent * inability to undergo catheterization (i.e. - history of urethral stricture) * inability to receive BCG therapy (i.e. - previous reaction with BCG) * no access to mobile phone * inability to respond to written conversations in English
About the study
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
What is being tested
- BCG delivery at home (other)
Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 50 · Started: Jul 5, 2025
Contact the study team
- Daniel Lee, PI, MD · Phone: 215-615-3780
Official record on ClinicalTrials.gov — NCT07048496
Locations in the U.S.
| Pennsylvania | Abramson Cancer Center, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.